前列地尔注射液对肝硬化患者肝功能变化的影响

Effect of alprostadil injection on liver function of patients with liver cirrhosis

目的观察前列地尔治疗肝硬化失代偿期患者的肝功能变化情况，评价其对肝硬化的疗效。方法选择肝硬化失代偿期患者112例，将其随机分成治疗组和对照组各56例。对照组采用常规护肝、利尿、支持等综合治疗，治疗组在常规综合治疗基础上加用前列地尔注射液，疗程均为21d。比较两组治疗前后肝功能指标（丙氨酸氨基转移酶、总胆红素、白蛋白、凝血酶原活动度）及腹水变化。结果两组治疗后肝功能均有所改善，相比治疗前差异均有统计学意义（P〈0．05）；治疗组丙氨酸氨基转移酶、总胆红素下降程度较对照组明显，腹水消退情况优于对照组，差异均有统计学意义（P〈0．05）；两组白蛋白、凝血酶原活动度升高程度比较差异未见统计学意义（P〉0．05）。结论前列地尔能明显的改善肝硬化患者肝功能，可以作为肝硬化失代偿期的有效治疗方法。

Objective To observe the efficacy of alphrostadil injection on patients with decompensated cirrhosis. Methods A toatal of 112 patients with decompensated cirrhosis were selected and randomly divided into treatment group and control group, with 56 cases in each group. The patients in control group were treated with conventional liver protection and support treatment, while the patients in treatment group were given alphrostadil injection on the basis of conventional treatment. The changes of liver function index including alanine aminotransferase （ALT） , total bilirubin （ TBIL）, albumin （ ALB ）, prothrombin cativity （PTA） , ascites and complications were compared. Results The levels of ALT, TBiL were significant decreased and the levels of ALB, PTA were increased after treatment in both groups （ P 〈 0. 05 ）. The changes of ALT, TBiL were more significant in treatment group compared with the control group （ P 〈 0. 05 ）. The regression of ascites in treatment group were more significant than those in the control group（P 〈 0.05 ）. There was no significant difference between the two groups in the change of ALB or PTA（P 〉 0. 05 ）. Conclusions Alphrostadil can improve the liver function of patients with liver cirrhosis, it had considerable effects on decompensated cirrhosis.